JP2010522214A - アデノシンレセプターアンタゴニストとしての置換ピリミジン - Google Patents

アデノシンレセプターアンタゴニストとしての置換ピリミジン Download PDF

Info

Publication number
JP2010522214A
JP2010522214A JP2009554781A JP2009554781A JP2010522214A JP 2010522214 A JP2010522214 A JP 2010522214A JP 2009554781 A JP2009554781 A JP 2009554781A JP 2009554781 A JP2009554781 A JP 2009554781A JP 2010522214 A JP2010522214 A JP 2010522214A
Authority
JP
Japan
Prior art keywords
compound
formula
group
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009554781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010522214A5 (OSRAM
Inventor
ヨンシェン チェン，
マニシャ ムーアヤニ，
デボラ スリー，
ジョン テリュー，
シャオフー チャン，
Original Assignee
アルミラル， エセ．アー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルミラル， エセ．アー． filed Critical アルミラル， エセ．アー．
Publication of JP2010522214A publication Critical patent/JP2010522214A/ja
Publication of JP2010522214A5 publication Critical patent/JP2010522214A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009554781A 2007-03-21 2008-03-21 アデノシンレセプターアンタゴニストとしての置換ピリミジン Withdrawn JP2010522214A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89619807P 2007-03-21 2007-03-21
PCT/US2008/057911 WO2008116185A2 (en) 2007-03-21 2008-03-21 Substituted pyrimidines as adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
JP2010522214A true JP2010522214A (ja) 2010-07-01
JP2010522214A5 JP2010522214A5 (OSRAM) 2012-04-19

Family

ID=39734991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009554781A Withdrawn JP2010522214A (ja) 2007-03-21 2008-03-21 アデノシンレセプターアンタゴニストとしての置換ピリミジン

Country Status (5)

Country Link
US (1) US20100249084A1 (OSRAM)
EP (1) EP2132197A2 (OSRAM)
JP (1) JP2010522214A (OSRAM)
CN (1) CN101687850A (OSRAM)
WO (1) WO2008116185A2 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2222638A2 (en) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating inflammation
EP2222639A1 (en) 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
CN102772800A (zh) * 2011-12-20 2012-11-14 同济大学 靶向腺苷受体a2bar的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
CN103664908A (zh) * 2013-12-10 2014-03-26 苏州大学 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物
SG10202111808WA (en) 2015-08-11 2021-11-29 Novartis Ag 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
GB2555264A (en) 2016-04-15 2018-04-25 Univ Oxford Innovation Ltd Adenosine receptor modulators for the treatment of circadian rhythm disorders
CN107286146B (zh) * 2017-07-05 2020-07-31 上海肇钰医药科技有限公司 作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途
CN109651358B (zh) * 2017-10-11 2023-04-07 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US27196A (en) * 1860-02-21 hitchcock
US78271A (en) * 1868-05-26 fatzingek
US3775326A (en) * 1972-04-17 1973-11-27 Addressograph Multigraph Pressure fixable electroscopic printing powder
JPS54117029A (en) * 1978-02-28 1979-09-11 Hokko Chem Ind Co Ltd Agricultural and horticultural microbicide
JPS54115384A (en) * 1978-02-28 1979-09-07 Hokko Chem Ind Co Ltd Ryrazolyl pyrimidine derivative, and agricultural and horticultural fungicides
JPS6059883B2 (ja) * 1978-05-08 1985-12-27 北興化学工業株式会社 農園芸用殺菌剤
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
DE3922735A1 (de) * 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
DE19710435A1 (de) * 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
DE19836697A1 (de) * 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000027824A1 (en) * 1998-11-12 2000-05-18 Elan Pharmaceuticals Substituted pyrimidine compositions and methods of use
CN1438890A (zh) * 2000-02-25 2003-08-27 弗·哈夫曼-拉罗切有限公司 腺苷受体调制剂
JP4272338B2 (ja) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
PT2316831E (pt) * 2002-11-21 2013-06-06 Novartis Ag 2-(morfolin-4-il)pirimidinas como inibidores da fosfatidilinositol (pi) quinase e a sua utilização no tratamento do cancro
SMAP200600024A (it) * 2003-12-15 2006-07-19 Almirall Prodesfarma Ag 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosia
US7582631B2 (en) * 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
US20080275064A1 (en) * 2005-04-11 2008-11-06 Deborah Slee Substituted Pyrimidines as Adenosine Receptor Antagonists

Also Published As

Publication number Publication date
WO2008116185A2 (en) 2008-09-25
WO2008116185A3 (en) 2009-03-12
CN101687850A (zh) 2010-03-31
EP2132197A2 (en) 2009-12-16
US20100249084A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
JP2010511727A5 (OSRAM)
JP2010511727A (ja) アデノシン受容体アンタゴニストとしての置換ピリミジン
CN102892761B (zh) 4-氨基嘧啶衍生物和它们作为腺苷a2a 受体拮抗剂
JP2010522214A (ja) アデノシンレセプターアンタゴニストとしての置換ピリミジン
KR102030305B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
JP2020143124A (ja) Ｕｓｐ３０阻害剤としての１−シアノ−ピロリジン化合物
AU2012323085B2 (en) PDE9i with imidazo pyrazinone backbone
JP2007514003A6 (ja) アデノシン受容体アンタゴニストとしての２，６−ビスヘテロアリール−４−アミノピリミジン
JP2007514003A (ja) アデノシン受容体アンタゴニストとしての２，６−ビスヘテロアリール−４−アミノピリミジン
US20120129852A1 (en) Azaindazoles as kinase inhibitors and use thereof
JPWO2001002400A1 (ja) 縮合イミダゾール化合物及び糖尿病治療薬
AU2018212593A1 (en) Tyrosine amide derivatives as Rho- kinase inhibitors
CN106535890A (zh) 5‑取代的吲唑‑3‑羧酰胺及其制备和应用
SK14282002A3 (sk) Deriváty 8-chinolínxantínu a 8-izochinolínxantínu, farmaceutická kompozícia, ktorá ich obsahuje, ich použitie a spôsob ich prípravy
JP2009507896A (ja) ヒスタミンｈ４受容体活性の調節剤としての２−アミノピリミジン誘導体
AU2004289518A1 (en) Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain
CN120322430A (zh) Pcsk9抑制剂及其使用方法
JP2007507443A (ja) ピリミジン−２−アミン誘導体およびａ２ｂアデノシン受容体アンタゴニストとしてのその使用
JP2009524682A (ja) アナバシン誘導体、医薬組成物およびその使用方法
US20130225583A1 (en) Substituted amino-triazolyl pde10 inhibitors
US20150166505A1 (en) Pyridinyl-substituted pyrazolyl carboxamides
JP5069119B2 (ja) 血管内皮成長因子（ｖｅｇｆ）受容体キナーゼインヒビターとしてのニコチンアミドピリジンウレア
EP1888565B1 (en) 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists
WO2016098793A1 (ja) 環状グアニジル基を有するチアゾール誘導体
US12492199B2 (en) Pyridopyrimidines as histamine H4-receptor inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110216

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20120615

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20120703